Related Experiment Video

Updated: Jul 14, 2026

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Effects of tyroserleutide on gene expression of calmodulin and PI3K in hepatocellular carcinoma

Lan Zhao1, Qian Zhao, Rong Lu

  • 1Department of Immunology, Tianjin Medical University, Tianjin 300070, China.

Journal of Cellular Biochemistry
|June 5, 2007
PubMed

Insights

Tyroserleutide (YSL) inhibits hepatocellular carcinoma by downregulating calmodulin (CaM) and phosphatidylinositol 3 kinase (PI3K) pathways. This tripeptide compound affects CaM protein and PI3K activity, suggesting a novel anti-tumor mechanism.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Hepatocellular carcinoma (HCC) is a major global health concern.
  • The Ca(2+)/calmodulin (CaM) pathway and phosphatidylinositol 3 kinase (PI3K) signaling are implicated in tumor development.
  • Tyroserleutide (YSL), a tripeptide, has shown prior inhibitory effects on HCC.

Purpose of the Study:

  • To investigate the anti-tumor mechanism of YSL in human hepatocellular carcinoma BEL-7402 xenograft tumors.
  • To determine the effects of YSL on CaM and PI3K pathway components.

Main Methods:

  • Studied YSL's impact on CaM protein expression and mRNA levels.
  • Assessed PI3K activity and the expression of PI3K regulatory (p85) and catalytic (p110alpha, p110gamma) subunits.
  • Utilized human hepatocellular carcinoma BEL-7402 xenograft tumor models in nude mice.

Main Results:

  • YSL significantly decreased CaM mRNA levels and protein expression.
  • YSL inhibited PI3K activity.
  • YSL reduced the mRNA and protein expression of the PI3K regulatory subunit p85 and the mRNA levels of PI3K catalytic subunits p110alpha and p110gamma.

Conclusions:

  • YSL exerts anti-tumor effects in HCC by downregulating CaM and PI3K signaling pathways.
  • YSL may overcome dysfunctional PI3K activity in tumors by influencing key signal transduction components.
  • These findings suggest YSL as a potential therapeutic agent for hepatocellular carcinoma.

More Related Videos

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...